Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Fucoidan in cancer therapy: from biomedical application to medicinal chemistry approach

Zheng Y., Fang S., Liu N., Zhang T., Huang Y., Li L.

Narrative Review on Chronic Inflammation, Immune Modulation, published in J Mater Sci Mater Med (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Mater Sci Mater Med (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41343091
PMCID
PMC12689777
DOI
10.1007/s10856-025-06962-8
Citations
4

Abstract (original English)

Biomaterials based on carbohydrate polymers, particularly modified polysaccharides, are gaining attention for cancer treatment due to their diverse properties and performance in clinical applications. While research on polysaccharides like chitosan and alginate is abundant, studies on chemically functionalized derivatives are limited. These derivatives, such as fucoidan, sulfated polysaccharides from brown seaweeds, offer minimal side effects and suitable drug release profiles. Fucoidan exhibits various biological activities, including anticancer, anti-inflammatory, and immunomodulatory effects, making it a promising candidate for cancer diagnosis and therapy. This review is the first to comprehensively explore the applications of fucoidan in combating cancer, focusing on its ability to inhibit tumor growth, induce cell death, and modify the tumor microenvironment. Additionally, the review discusses nanostructured chemically modified fucoidan-based biomaterials, which show potential for hydrogel engineering and enhanced drug delivery systems. These advancements highlight the significance of chemical modifications and mechanistic insights into targeted drug delivery and controlled release rates. Incorporating fucoidan into nanocarriers improves its biodegradability, biocompatibility, and structural stability, facilitating surface modifications that enhance targeting efficiency a

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansNeoplasmsPolysaccharidesAntineoplastic AgentsBiocompatible MaterialsHydrogelsDrug Delivery SystemsChemistry, PharmaceuticalTumor Microenvironment

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research